VKTX - Viking Therapeutics, Inc.
| Previous Close | 7.86 |
| Open | 7.93 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1100 |
| Day's Range | 7.84 - 8.15 |
| 52 Week Range | 6.97 - 24.00 |
| Volume | 1,359,655 |
| Avg. Volume | 2,794,371 |
| Market Cap | 586.468M |
| Beta (3Y Monthly) | 3.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.36 |
| Earnings Date | Nov 6, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.13 |
- Market Realist•4 days ago
How Viking Therapeutics Is Positioned
Viking Therapeutics (VKTX) stock closed at $7.98 on June 12, 2.70% higher than its previous close, 14.49% above its 52-week low of $6.97, and 66.75% below its 52-week high of $24.
- Market Realist•4 days ago
What Analysts Recommend for CBAY and VKTX
This year, CymaBay Therapeutics (CBAY) has fallen 21.60% and Viking Therapeutics (VKTX) has risen 4.31%. While both clinical-stage companies focus on advancing their nonalcoholic steatohepatitis research and development programs, Viking seems to be ahead, considering its successful Phase 2 trials.
- Motley Fool•18 days ago
3 Stocks to Buy and Hold for the Next 50 Years
The catalysts these companies enjoy could translate into big returns for shareholders in the coming decades.
- PR Newswire•21 days ago
Viking Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO , May 28, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
- Motley Fool•last month
3 Small-Cap Biotech Stocks You Can Buy Right Now
They're risky. You'll have to wait years before any significant revenue comes in. But these biotech stocks could be huge winners.
- Simply Wall St.•last month
Have Insiders Been Buying Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- Insider Monkey•last month
Were Hedge Funds Right About Dumping Viking Therapeutics, Inc. (VKTX) ?
We can judge whether Viking Therapeutics, Inc. (NASDAQ:VKTX) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best […]
- Thomson Reuters StreetEvents•last month
Edited Transcript of VKTX earnings conference call or presentation 2-May-19 8:30pm GMT
Q1 2019 Viking Therapeutics Inc Earnings Call
- Motley Fool•last month
3 Top Biotech Stocks to Buy in May
These three biotech stocks could be prime comeback candidates.
- Zacks Small Cap Research•2 months ago
VKTX: Pre-IND Meeting with FDA in Summer 2019; Phase 2b NASH Trial to Initiate 2H19…
Viking Therapeutics, Inc. (VKTX) is currently preparing for the initiation of a Phase 2b clinical trial of VK2809, the company’s thyroid beta receptor (TRβ) agonist, for the treatment of nonalcoholic steatohepatitis (NASH). While details of the trial have yet to finalized, we do anticipate the trial including biopsy-confirmed NASH patients with F2 and F3 fibrosis (although there are likely to be a small number with F1 fibrosis). Regarding the upcoming trial, based on the length for competitors Phase 2b trials we estimate that if started in the second half of 2019 topline data would probably be available in the first half of 2021, although 4Q20 isn’t out of the question.
Motley Fool•2 months agoViking Therapeutics Inc (VKTX) Q1 2019 Earnings Call Transcript
VKTX earnings call for the period ending March 31, 2019.
- PR Newswire•2 months ago
Viking Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today - New Data from Phase 2 Study of VK2809 Presented at EASL 2019; Results Demonstrate Robust Efficacy at Doses as Low as 5 mg Daily - Phase 2b Study of VK2809 ...
- Motley Fool•2 months ago
2 Reasons Gilead Sciences' NASH Program Could Bounce Back
It's been a rough few years, but an unexpected partnership could put the biotech's liver disease program back on top.
- PR Newswire•2 months ago
Viking Therapeutics to Report Financial Results for First Quarter 2019 on May 2, 2019
Conference Call Scheduled for Thursday, May 2 at 4:30 p.m. Eastern Time SAN DIEGO , April 25, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical ...
- Market Realist•2 months ago
VKTX or ENTA: What to Expect from Revenue Growth in 2019
What Are Analysts Recommending for VKTX and ENTA?(Continued from Prior Part)Growth drivers In November 2018, Viking Therapeutics (VKTX) issued a press release announcing positive results from its Phase 2 trial evaluating the efficacy of the 1-mg dose
- Market Realist•2 months ago
What Are Analysts Recommending for VKTX and ENTA?
What Are Analysts Recommending for VKTX and ENTA?Stock price movementOn April 12, Viking Therapeutics (VKTX) closed at $9.35, 6.22% lower than its previous closing price, 153.39% higher than its 52-week low of $3.69, and 61.04% below its 52-week
- Zacks Small Cap Research•2 months ago
VKTX: VK2809 5 mg Data Presented at EASL…
In addition, all nine patients in the 5 mg cohort experienced ≥ 30% reduction in liver fat and 77.8% were ‘super-responders’, defined as experiencing ≥ 50% reduction in liver fat. For those who may argue that the two patient populations are too dissimilar to offer a valid comparison, we believe that the very similar placebo responses seen in both outcomes in the table below indicate that the two populations are in fact quite similar.
- PR Newswire•2 months ago
Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019
Patients Receiving 5 mg Daily Doses of VK2809 Demonstrated Statistically Significant Median Reduction in Liver Fat Content of 53.8% 88% of Patients Receiving VK2809 Experienced ≥ 30% Reduction in Liver ...
- Motley Fool•2 months ago
Why Viking Therapeutics Stock Perked Up in March
Viking's shares received a boost from a pair of catalysts last month.
- Motley Fool•2 months ago
Here's Why Investors Are Betting Against These 2 Biotech Stocks
Are intrepid short-sellers taking advantage of misguided enthusiasm?
- PR Newswire•2 months ago
Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019
Late-Breaker Presentation to Highlight Efficacy, Safety and Tolerability Results from 12-Week Phase 2 Trial Including New Data from Study's 5 mg Treatment Arm SAN DIEGO , April 4, 2019 /PRNewswire/ -- Viking ...
- Motley Fool•3 months ago
3 Top Value Stocks to Buy Right Now
Bargain hunting? These out-of-favor biotech and e-commerce stocks should appeal to value investors.
- TheStreet.com•3 months ago
The Best Approach to Trading Lyft
Every day this week the indices have opened on an upbeat note and then sold off. If you are interested in trading it the best approach is to wait at least 30 minutes to an hour after it opens and watch for a trading range to develop. The trading range provides a mechanism for risk control and nothing more.
